Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.30 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599314 | 0.74 | ALDH1A1 (0.38) | ALDH1A1MAPTTDP1L3MBTL1BAZ1A | |
| SCHEMBL4448981 | 0.72 | KDM4E (0.35) | MAPTTDP1PGK1 | |
| SCHEMBL4450868 | 0.71 | CYSLTR2 (0.33) | MAPTTDP1 | |
| SCHEMBL4445403 | 0.71 | MAPT (0.34) | MAPTTDP1 | |
| SCHEMBL4450873 | 0.71 | KDM4E (0.39) | MAPTTDP1 | |
| SCHEMBL14681823 | 0.70 | GPR84 (0.41) | ALDH1A1MAPTTDP1L3MBTL1VCAM1 | |
| SCHEMBL1025369 | 0.70 | ALDH1A1 (0.40) | ALDH1A1MAPTTDP1BAZ1A | |
| SCHEMBL7894568 | 0.67 | ATM (0.42) | ALDH1A1MAPTTDP1BAZ1AVCAM1 | |
| SCHEMBL1994756 | 0.67 | MAPT (0.45) | ALDH1A1MAPTTDP1L3MBTL1BAZ1A | |
| SCHEMBL11980460 | 0.67 | BAZ1A (0.37) | ALDH1A1MAPTBAZ1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-7482484-B2 | Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2006-05-25 | — | — | US | disclosed |
| EP-1583738-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GmbH (DE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063148-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | NR1H3, LDLR, NR1H2 | ALDH1A1 2283/4885MAPT 4833/4885TDP1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.